Drug Profile
Naltrexone - Biostax/Statera BioPharma
Alternative Names: CYTO 201; CYTO-201 - Biostax; CYTO-205; IRT-103; IRT-104; LDN - Biostax; Lodonal; Low-dose naltrexone - Biostax; STAT 201; STAT 205; STAT-200 AIMS™; STAT-200: noroxymorphone-n-substituted-methyl cyclopropyl analogsLatest Information Update: 05 Sep 2023
Price :
$50
*
At a glance
- Originator Nonindustrial source
- Developer Biostax; GB Pharma Holdings; Penn State Milton S. Hershey Medical Center; Statera BioPharma
- Class Anti-inflammatories; Antineoplastics; Antivirals; Cyclopropanes; Drug withdrawal therapies; Ethers; Eye disorder therapies; Irritable bowel syndrome therapies; Ketones; Morphinans; Non-opioid analgesics; Small molecules
- Mechanism of Action Opioid receptor antagonists; Virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Marketed Autoimmune disorders; Cancer
- Registered HIV infections
- Phase II Crohn's disease
- Phase I COVID 2019 infections
- No development reported Cervical cancer
Most Recent Events
- 29 Aug 2023 Biostax Corp signs a research collaboration agreement with Immgenuity to focus on using naltrexone and JKB 122 with Immgenuity’s IMTV014 both independently and together to achieve remission with HIV patients
- 20 Apr 2023 Statera Biopharma amends royalty-bearing license agreement with Biostax for the rights to low dose naltrexone
- 09 Jun 2022 Cytocom files an IND application with the US FDA in USA for COVID-2019 infections (Adjunctive therapy)